Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Capecitabine followed by SBRT in Pancreatic Cancer
NCT01360593Phase 2Completed
- Start
- Jul 2011
- Primary completion
- Mar 2016
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, capecitabine in pancreatic adenocarcinoma (PDAC). Started Jul 2011; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01360593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360593.